Avalon Globocare CORP

Change Agents Corporation has entered into a Business Loan and Security Agreement for $825,000, alongside a Confessed Judgment Secured Promissory Note, and issued shares in connection with a forbearance agreement.

Change Agents Corporation has entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC, establishing a $10 million equity line of credit and issuing a warrant for 925,925 shares.

Avalon GloboCare Corp. has officially changed its name to Change Agents Corporation and will trade under the new ticker symbol CHGA, signaling a strategic shift towards agentic AI software solutions.

Avalon GloboCare Corp. announced a $400,000 financing through the sale of Series F Convertible Preferred Stock and common stock to an accredited investor.

Avalon GloboCare Corp. shareholders approved key proposals including a reverse stock split and a new 2026 incentive plan.

Avalon GloboCare issued $500,000 in promissory notes and announced key executive leadership changes.

Avalon GloboCare Corp. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.48 million and highlighting strategic shifts towards AI-driven content technology and the KetoAir breathalyzer.

Avalon GloboCare Corp. reported a significant increase in net loss for the nine months ended September 30, 2025, alongside a going concern warning and a CEO resignation.

Avalon GloboCare Corp. reported a substantial increase in net loss for Q2 and H1 2025, alongside a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Avalon GloboCare's Q1 2025 shows increased revenue from real property rentals but a larger net loss, raising concerns about the company's ability to continue as a going concern.

Avalon GloboCare Corp. saw a rise in rental income but experienced ongoing net losses in the third quarter of 2024, according to its latest financial report.

Avalon GloboCare Corp. saw a revenue increase in its real property segment but continues to experience net losses in the second quarter of 2024, while also restructuring its operations.

Avalon GloboCare Corp. files its annual report on Form 10-K, detailing its financial performance, strategic shifts towards precision diagnostic consumer products, and a pending merger with YOOV Group Holding Limited.

Avalon GloboCare Corp.'s annual 10-K filing details a strategic pivot towards precision diagnostics and clinical laboratory services, alongside updates on financial performance and risk factors.

Wenzhao Lu, a Director of Avalon GloboCare Corp., received 200,000 shares of common stock on June 29, 2026.

Steven Andrew Sanders, a Director of Avalon GloboCare Corp., received 200,000 shares of common stock on June 29, 2026.

Michael Mathews, a Director of Avalon GloboCare Corp., received 100,000 shares of common stock on June 29, 2026.

Meng Li, Interim CEO of Avalon GloboCare Corp., received 400,000 shares of common stock on June 29, 2026.

Luisa Ingargiola, Chief Strategy Officer of Avalon GloboCare Corp., received 400,000 shares of common stock on June 29, 2026.

Lourdes Felix, a Director of Avalon GloboCare Corp., received 100,000 shares of common stock on June 29, 2026.

Avalon GloboCare Corp. schedules its 2026 Annual Meeting to vote on a reverse stock split, a new equity incentive plan, and the ratification of prior warrant issuances.

Avalon GloboCare Corp. calls a special meeting to approve multiple equity issuances and a reverse stock split to maintain Nasdaq listing and manage its capital structure.

Avalon GloboCare Corp. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 30, 2025, alongside the resignation of CEO Dr. David Jin and the appointment of Meng Li as interim CEO.

Avalon GloboCare Corp. is convening its 2024 Annual Meeting of Stockholders to vote on key proposals including a reverse stock split, share issuance, director elections, and auditor ratification.

Avalon GloboCare Corp. has filed a registration statement for the resale of up to 19,436,278 shares of its common stock by selling stockholders.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Avalon Globocare Corp.'s common stock as of March 31, 2026.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 7.0% passive beneficial ownership stake in Avalon GloboCare Corp.